First National Bank & Trust Co. of Newtown Decreases Holdings in Johnson & Johnson (NYSE:JNJ)

First National Bank & Trust Co. of Newtown reduced its stake in Johnson & Johnson (NYSE:JNJ) by 6.4% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 37,161 shares of the company’s stock after selling 2,532 shares during the quarter. Johnson & Johnson accounts for approximately 1.1% of First National Bank & Trust Co. of Newtown’s portfolio, making the stock its 16th largest holding. First National Bank & Trust Co. of Newtown’s holdings in Johnson & Johnson were worth $5,374,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Knuff & Co LLC lifted its position in shares of Johnson & Johnson by 0.7% in the third quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after purchasing an additional 64 shares in the last quarter. Vertex Planning Partners LLC grew its holdings in shares of Johnson & Johnson by 1.3% in the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock valued at $844,000 after acquiring an additional 65 shares in the last quarter. Freedom Day Solutions LLC increased its position in shares of Johnson & Johnson by 1.1% in the third quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company’s stock valued at $1,016,000 after acquiring an additional 66 shares during the last quarter. Werba Rubin Papier Wealth Management raised its holdings in Johnson & Johnson by 3.3% during the fourth quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock worth $301,000 after acquiring an additional 66 shares in the last quarter. Finally, Corepath Wealth Partners LLC grew its stake in Johnson & Johnson by 3.7% in the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company’s stock valued at $287,000 after purchasing an additional 70 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 1.7 %

Shares of NYSE JNJ opened at $162.35 on Monday. The firm’s fifty day moving average is $148.93 and its 200 day moving average is $155.86. The company has a market cap of $390.87 billion, a price-to-earnings ratio of 24.41, a PEG ratio of 2.56 and a beta of 0.52. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the previous year, the business posted $2.29 EPS. The company’s quarterly revenue was up 5.3% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on JNJ. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Guggenheim lifted their price objective on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Citigroup decreased their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Finally, Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.